What Is a Normal Fasting Insulin Level in Pregnancy?

What Is a Normal Fasting Insulin Level in Pregnancy?

For most pregnant women, a fasting insulin level below 10 µIU/mL is considered optimal, with many functional medicine practitioners targeting under 8 µIU/mL in the first trimester. The main caveat: insulin naturally rises across pregnancy — physiological insulin resistance in the second and third trimesters is expected and protective for fetal glucose supply. The exception is anyone already entering pregnancy with insulin resistance, where that baseline rise can push levels into a range that increases gestational diabetes risk significantly.

---

Why Fasting Insulin Matters More Than Glucose Alone in Pregnancy

Standard prenatal care typically measures fasting blood glucose and — later — the oral glucose tolerance test (OGTT). Fasting insulin is rarely ordered on a routine prenatal panel, yet it reflects pancreatic compensation before glucose has even begun to rise. A woman can have a completely normal fasting glucose (70–85 mg/dL) and still be producing two or three times the insulin needed to hold it there.

This compensatory hyperinsulinemia matters in pregnancy for several reasons:

• Fetal macrosomia risk: Elevated maternal insulin drives glucose across the placenta. The fetal pancreas then over-secretes its own insulin, promoting excess fat storage and large-for-gestational-age (LGA) birth weight.
• Preeclampsia association: Hyperinsulinemia is independently associated with hypertensive disorders of pregnancy in prospective cohort data (Ramsay et al., BJOG 2002; PMID: 12078107).
• Postpartum metabolic trajectory: Women who enter pregnancy with elevated fasting insulin have a significantly higher 10-year risk of type 2 diabetes, making the pregnancy window a critical detection opportunity.

The mechanism behind the preeclampsia link is worth unpacking further. Chronic hyperinsulinemia activates the sympathetic nervous system, increases renal sodium reabsorption, and impairs endothelial nitric oxide synthase — all pathways that raise blood pressure independently of glucose. In the placenta specifically, elevated insulin promotes trophoblast overgrowth and disrupts spiral artery remodeling, which is the upstream event in most preeclampsia cases. This means that even a fasting insulin reading of 14–16 µIU/mL — below the threshold most labs would flag — can be driving vascular pathology in a pregnant woman with no glucose abnormality on her chart.

The relationship between fasting insulin and hormonal health extends beyond glucose — insulin influences sex hormone-binding globulin, androgen production, and thyroid function, all of which are especially active during gestation.

---

Reference Ranges: What Do the Numbers Actually Mean?

There is no single universally agreed-upon "normal" for fasting insulin in pregnancy, partly because trimester matters and partly because conventional lab reference ranges (often 2–25 µIU/mL) are built for the general adult population, not pregnant women specifically. Here is how practitioners typically interpret the numbers:

These interpretive ranges align with functional medicine thresholds used in clinical practice and with data from the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study, which demonstrated dose-dependent relationships between maternal glucose and insulin and adverse outcomes across the full range — not just above a diagnostic threshold (HAPO Study Cooperative Research Group, NEJM 2008; PMID: 18463375).

Trimester adjustments matter. A fasting insulin of 12 µIU/mL at 8 weeks of gestation carries different weight than the same number at 28 weeks, when physiological insulin resistance peaks. Longitudinal data from Catalano and colleagues established that insulin-stimulated glucose disposal decreases by approximately 50–60% from the first to the third trimester in healthy women, and fasting insulin rises accordingly as a compensatory mechanism (Catalano et al., American Journal of Obstetrics and Gynecology 1991; PMID: 1951535). Understanding your baseline before or early in pregnancy is therefore the most clinically meaningful data point.

HOMA-IR — calculated as fasting insulin (µIU/mL) × fasting glucose (mmol/L) ÷ 22.5, or in US units as fasting insulin × fasting glucose (mg/dL) ÷ 405 — provides a composite index that is more stable than either marker alone. A HOMA-IR above 2.5 in the first trimester is generally considered elevated for pregnancy, though some researchers set the threshold at 2.0 for women with pre-existing PCOS or a prior GDM diagnosis. The HOMA-IR threshold of 2.14 has been validated against euglycemic-hyperinsulinemic clamp data as a reliable clinical cutoff in non-pregnant adults (Matthews et al., Diabetologia 1985; PMID: 3899825), and most prenatal applications adapt this range upward slightly to account for physiological insulin resistance.

---

Signs of High Insulin During Pregnancy

Because fasting insulin is not a standard prenatal test, many women experience the effects of elevated levels without knowing the underlying cause. Common signs worth discussing with a care provider include:

• Persistent fatigue beyond typical first-trimester exhaustion, particularly after meals
• Intense carbohydrate cravings and difficulty feeling satisfied after eating
• Rapid gestational weight gain, especially in the abdomen
• Acanthosis nigricans — darkening of skin folds at the neck, underarms, or groin
• Elevated fasting glucose on routine labs (even readings of 92–99 mg/dL should prompt an insulin check)
• Polycystic ovary syndrome (PCOS) history, since PCOS-related insulin resistance does not resolve with conception and typically worsens in mid-pregnancy
• Swelling or blood pressure creep in the second trimester, which can be early hypertensive signaling
• Skin tags at friction sites (neck, axilla, groin) — a frequently overlooked cutaneous marker of chronic hyperinsulinemia

It is worth noting that many of these symptoms — fatigue, cravings, weight gain — overlap heavily with normal pregnancy experience. This overlap is exactly why measuring the number, rather than inferring from symptoms alone, is valuable. If you have been tracking what causes fasting insulin to be out of range before pregnancy, that baseline becomes a critical reference point once you conceive.

One additional clinical sign that is often missed: reactive hypoglycemia episodes — shakiness, anxiety, or brain fog approximately 90–120 minutes after a high-carbohydrate meal — can indicate an exaggerated insulin surge followed by an overcorrection. In a pregnant woman, these episodes represent a glucose trough that the fetus also experiences, making meal composition more consequential than most standard prenatal guidance acknowledges.

---

How Insulin Resistance Develops and Progresses in Pregnancy

Physiological insulin resistance during pregnancy is orchestrated primarily by placental hormones — human placental lactogen (hPL), progesterone, cortisol, and estrogen all reduce peripheral insulin sensitivity from roughly 20 weeks onward. This ensures a steady glucose supply to the fetus even in a fasted state.

In women who begin pregnancy with optimal insulin sensitivity, the pancreas handles this demand easily. In women who enter with subclinical insulin resistance, the added placental hormone burden can exhaust pancreatic beta-cell reserve, producing a trajectory toward gestational diabetes mellitus (GDM) that becomes clinically apparent on the OGTT at 24–28 weeks.

A meta-analysis of prospective studies found that pre-pregnancy fasting insulin was one of the strongest independent predictors of GDM, with each standard deviation increase in pre-pregnancy fasting insulin associated with a meaningfully increased risk of GDM diagnosis (Metzger et al., Diabetes Care 2007; PMID: 17596476). The practical implication: a woman with a fasting insulin of 14 µIU/mL pre-conception is not merely "borderline" — she is beginning pregnancy on a trajectory that placental hormones will amplify significantly by week 24.

hPL specifically deserves attention as a mechanism driver. It is structurally homologous to growth hormone and acts as a counter-regulatory hormone to insulin at the adipocyte and muscle cell level — downregulating GLUT4 translocation and reducing insulin receptor substrate-1 (IRS-1) phosphorylation. The net effect is that every unit of hPL secreted by the growing placenta incrementally worsens maternal insulin resistance in a dose-dependent, gestation-length-dependent manner. Women with larger placentas (multiples, macrosomic fetuses) produce more hPL and experience proportionally greater insulin resistance, which is one reason GDM rates in twin pregnancies are nearly double those in singleton gestations.

This is why the question of fasting insulin is not merely academic — it is a modifiable risk factor with a measurable pre-pregnancy window for intervention.

---

Foods and Nutrients That Influence Insulin During Pregnancy

Dietary composition has a well-documented effect on fasting insulin, and this relationship does not disappear during pregnancy. A few key mechanisms:

Glycemic load matters more than glycemic index. High glycemic load meals drive larger insulin pulses throughout the day, and habitual high-GL eating patterns are associated with elevated fasting insulin even in the absence of frank hyperglycemia. A randomized trial in women at risk for GDM found that a low-glycemic-index diet reduced fasting insulin by approximately 20% over 12 weeks compared to a conventional higher-GI diet (Moses et al., Diabetes Care 2006; PMID: 16873782). The trial enrolled 70 women, used an isocaloric design, and found the low-GI group also had significantly lower rates of LGA infants — a downstream marker of the insulin effect.

Protein at breakfast stabilizes the morning insulin curve. Studies in both pregnant and non-pregnant women consistently show that replacing refined carbohydrate at breakfast with protein (eggs, Greek yogurt, legumes) lowers postprandial insulin excursions and reduces fasting insulin the following morning. The mechanism involves glucagon co-secretion: protein stimulates both insulin and glucagon, whereas carbohydrate stimulates insulin alone. The glucagon signal attenuates the depth of the postprandial insulin trough and reduces reactive hypoglycemia.

Fiber slows gastric emptying and attenuates insulin response. Soluble fiber from oats, legumes, and vegetables reduces the glycemic response to mixed meals, a benefit that compounds over time into lower fasting insulin levels. Viscous fibers — beta-glucan, psyllium, pectin — are the most effective subclass, with meta-analytic evidence showing reductions in postprandial glucose of 0.4–0.9 mmol/L per 10g of added viscous fiber daily.

Specific nutrients with mechanistic data:

For a detailed look at how supplements affect fasting insulin in women, the mechanistic and dosing evidence are worth reviewing alongside any prenatal supplementation decisions.

---

Gestational Diabetes vs. Insulin Resistance: Are They the Same Thing?

Not exactly — but they exist on a continuum. Gestational diabetes mellitus (GDM) is a clinical diagnosis made via standardized glucose testing, typically the one-hour glucose challenge followed by a three-hour OGTT. A positive GDM diagnosis requires glucose to meet or exceed defined thresholds.

Insulin resistance can exist for years — or an entire pregnancy — before glucose thresholds are crossed. This means:

• A woman can have significant fasting hyperinsulinemia and pass her OGTT
• Her fetal and placental outcomes may still be affected by that insulin exposure
• She is at high risk of converting to GDM in a subsequent pregnancy

The relationship between fasting insulin and HbA1c helps explain why some women have persistently elevated HbA1c in the upper-normal range (5.4–5.6%) alongside elevated insulin but remain below GDM diagnostic criteria. Both numbers together tell a more complete story than either alone.

If you are trying to understand whether a normal fasting glucose means you are in the clear, the answer is: not necessarily. As explored in detail on why fasting insulin can be normal while you still feel awful, postprandial insulin dysregulation does not always show up on a single morning fasting measurement.

It is also worth understanding that GDM itself is a heterogeneous diagnosis. Approximately 30–40% of women diagnosed with GDM have predominantly beta-cell secretory failure (insufficient insulin production rather than insulin resistance), while 60–70% have classical peripheral insulin resistance with compensatory hyperinsulinemia. Fasting insulin helps distinguish between these phenotypes: a woman with GDM and a low fasting insulin likely has a secretory defect; a woman with GDM and a fasting insulin above 15 µIU/mL is driving her glucose elevation through resistance, not secretory failure. This distinction has direct implications for management — the former group benefits most from exogenous insulin therapy, while the latter may respond well to lifestyle and metabolic interventions earlier in the pregnancy.

---

When to Ask Your Provider for an Insulin Test

Fasting insulin is not a standard prenatal order. You will likely need to request it specifically. Consider asking for a fasting insulin level alongside your routine first-trimester labs if:

1. You have a personal or family history of type 2 diabetes or GDM
2. You have PCOS or a prior diagnosis of insulin resistance
3. Your pre-pregnancy BMI was above 25
4. You experienced significant weight gain between pregnancies
5. Your fasting glucose is in the 90–99 mg/dL range even on routine labs
6. You have classic signs of insulin resistance (skin tags, acanthosis nigricans, persistent fatigue after carbohydrate-heavy meals)

Most labs process fasting insulin with a standard venous draw, collected after an 8–12 hour overnight fast. Timing matters: even a 6-hour fast rather than a full overnight fast can underestimate fasting insulin by 15–25%, making results less comparable across visits. Request that the draw be collected before any food or caloric beverage, including coffee with additives.

If your provider is unfamiliar with the clinical utility of first-trimester fasting insulin, whether women should get fasting insulin tested covers the evidence base for routine screening in detail and may be a useful resource to share with your care team.

---

What This Means for Your Formula

Ones uses lab data — including fasting insulin where available — to inform personalized capsule formulas, and several ingredients in its catalog are specifically relevant to insulin signaling during the preconception and prenatal period.

Magnesium Glycinate is one of the most clinically supported micronutrients for insulin receptor function. A systematic review of 18 RCTs found magnesium supplementation significantly reduced fasting insulin in individuals with hypomagnesemia, which is disproportionately common in pregnancy as renal magnesium excretion increases (Simental-Mendía et al., European Journal of Clinical Nutrition 2016; PMID: 26526498). The effect size in hypomagnesemic individuals was a mean reduction of approximately 0.67 µIU/mL in fasting insulin — modest in isolation, but meaningful when combined with dietary changes and sustained over a full trimester. Ones includes magnesium glycinate in a bioavailable form, dosed to therapeutic levels rather than the low amounts found in standard prenatal multivitamins.

Zinc plays a direct role in insulin synthesis, storage, and secretion from pancreatic beta cells, where it is required for the crystallization of hexameric insulin within secretory granules. Zinc deficiency — which is more prevalent in pregnancy due to increased fetal demand — impairs both the first-phase and second-phase insulin response to glucose. Ones formulas include zinc at clinically relevant doses calibrated to individual lab levels, which is particularly meaningful for pregnant and preconception users whose zinc requirements increase substantially. Reviewing what constitutes a normal zinc level in pregnancy before supplementing is worthwhile, since both deficiency and excess carry gestational risks.

Omega-3 (EPA/DHA) reduces systemic inflammation and improves adiponectin levels, both of which support insulin sensitivity. A Cochrane review of omega-3 supplementation in pregnancy found benefits across multiple metabolic markers, with particular relevance to women at risk for GDM (Middleton et al., Cochrane Database 2018; PMID: 29921055). Ones includes pharmaceutical-grade EPA/DHA dosed to the ranges used in clinical trials — typically 1,000–2,000 mg combined EPA/DHA — rather than the token amounts in most prenatal blends.

Ones formulas are built from your actual biomarker data — not a generic prenatal blend — which means that if your fasting insulin is elevated, the formula can be calibrated around that specific finding rather than treating all pregnancies identically.

---

Key Takeaways

• Optimal fasting insulin in pregnancy is generally below 10 µIU/mL, with under 8 µIU/mL considered excellent sensitivity, particularly in the first trimester.
• Insulin naturally rises across pregnancy — a reading that is borderline in the first trimester should be interpreted differently at 28 weeks, when physiological insulin resistance peaks by 50–60% from baseline.
• Fasting glucose alone misses early insulin resistance — many women with perfectly normal glucose are running on compensatory hyperinsulinemia that affects fetal growth, blood pressure, and long-term metabolic health.
• Signs of high insulin (fatigue, intense carb cravings, reactive hypoglycemia episodes, acanthosis nigricans, skin tags) warrant a direct insulin measurement — not just reassurance from a normal glucose number.
• Pre-pregnancy fasting insulin is the most actionable data point — the earlier insulin resistance is identified, the larger the window for meaningful intervention before placental hormones amplify the problem.
• Key nutrients — magnesium glycinate, zinc, and omega-3 EPA/DHA — have mechanistic and clinical evidence supporting their role in insulin signaling, and their impact is most precise when dosed to your actual lab values rather than generic prenatal formulas.

Always consult your OB, midwife, or a licensed healthcare provider before making changes to your prenatal supplementation or diet based on lab values.